METHODS:
Sections of paraffin-embedded ileal and colonic biopsies from healthy controls (HC) (negative control, number of biopsies (N)=20), Crohn patients (positive control, N=20), SpA patients without gut inflammation (N=30) and SpA patients with subclinical gut inflammation (N=28) were immunostained for VEGF and for CD31 and blindly scored by computerized morphometric analysis using specialized software.
RESULTS:
Both intestinal VEGF activity and mucosal vascular density (MVD) were higher in SpA patients versus healthy controls, independent of the presence of chronic gut inflammation (HC vs SpA patients without gut inflammation: P<0,05 and P<0,01 respectively for VEGF and MVD; HC vs SpA patients with chronic gut inflammation: P<0,001 both for VEGF and MVD). Nevertheless, presence of subclinical chronic gut inflammation was associated with much stronger intestinal VEGF expression and mucosal vascularization, resembling the pattern of Crohn's disease (SpA patients with gut inflammation vs SpA patients without gut inflammation: P<0,001 for VEGF; P<0,01 for MVD). Unlike in Crohn patients however, the high VEGF activity and MVD observed in SpA patients with chronic gut inflammation was not clearly dependent on the presence of active inflammation in the biopsy (epithelial infiltration of polymorphonuclear cells, ulcerations, granulomas).
CONCLUSION:
A pro-angiogenic intestinal phenotype is observed in SpA patients which, unlike in Crohn's disease, is not clearly dependent of active gut inflammation.
